Published: March 4, 2026 at 9:46 pm
The share price of Oxford Nanopore Technologies plc surged from 114.5p to 124.4p today (Wednesday) before closing on 116p.
Earlier this week Francis Van Parys succeeded founder Gordon Sanghera as CEO.
The FTSE 250 MedTech is eyeing profitability after also reporting its results for 2025.
The company’s share price opened at 112.90p today and climbed most of the day before a late fall saw it close on 116p.
The DNA sequencing specialist reported revenues of £223.9m, up 22.2 per cent year-on-year, while adjusted EBITDA losses shrank 31.2 per cent to £86.7m. Actual losses shrank 1 per cent to £145.2m.
The group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA.
The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.
Oxford Nanopore’s technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.